Polaryx Therapeutics Reports Third Quarter 2026 Financial Results
Polaryx Therapeutics announced its financial results for the third quarter of 2026, reporting continued zero revenue and an increased operating loss.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Polaryx Therapeutics announced its financial results for the third quarter of 2026, reporting continued zero revenue and an increased operating loss.
Polaryx Therapeutics has officially activated the first clinical trial site for its SOTERIA Phase 2 basket trial, which is evaluating the company's lead candidate, PLX-200.
Webuy Global shares jumped 15% premarket after H1 revenue nearly doubled to $14.31M and net loss narrowed; Game Your Game led gainers, Masonglory fell.
Filed: 2026-09-01 AccNo: 0001213900-26-096235 Size: 218 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits